source
- MapLight dives despite positive data for schizophrenia drugShares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
- MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readoutWhile MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb's Cobenfy is likely to hold its market share.